.medscape.org/journal/jnccn ; (4) view/print certificate. Release date: October 7, 2011; Expiration date: October 7, 2012. Learning Objectives Upon completion of this activity, participants will be able to: Distinguish the most common genetic abnormality in multiple myeloma
Kenneth C. Anderson, Melissa Alsina, Djordje Atanackovic, J. Sybil Biermann, Jason C. Chandler, Caitlin Costello, Benjamin Djulbegovic, Henry C. Fung, Cristina Gasparetto, Kelly Godby, Craig Hofmeister, Leona Holmberg, Sarah Holstein, Carol Ann Huff, Adetola Kassim, Amrita Y. Krishnan, Shaji K. Kumar, Michaela Liedtke, Matthew Lunning, Noopur Raje, Seema Singhal, Clayton Smith, George Somlo, Keith Stockerl-Goldstein, Steven P. Treon, Donna Weber, Joachim Yahalom, Dorothy A. Shead and Rashmi Kumar
American Cancer Society has estimated 26,850 new multiple myeloma (MM) cancer cases in the United States in 2015, with an estimated 11,240 deaths. 1 The mean age of affected individuals is 62 years for men (75% >70 years of age) and 61 years for women (79
Charise Gleason, Ajay Nooka and Sagar Lonial
. Improved survival in multiple myeloma and the impact of novel therapies . Blood 2008 ; 111 : 2516 – 2520 . 2 Silberman J Lonial S . Review of peripheral neuropathy in plasma cell disorders . Hematol Oncol 2008 ; 26 : 55 – 65 . 3
Shaji K. Kumar, Natalie S. Callander, Melissa Alsina, Djordje Atanackovic, J. Sybil Biermann, Jason C. Chandler, Caitlin Costello, Matthew Faiman, Henry C. Fung, Cristina Gasparetto, Kelly Godby, Craig Hofmeister, Leona Holmberg, Sarah Holstein, Carol Ann Huff, Adetola Kassim, Michaela Liedtke, Thomas Martin, James Omel, Noopur Raje, Frederic J. Reu, Seema Singhal, George Somlo, Keith Stockerl-Goldstein, Steven P. Treon, Donna Weber, Joachim Yahalom, Dorothy A. Shead and Rashmi Kumar
Multiple myeloma (MM) is a malignant neoplasm of plasma cells that accumulate in bone marrow, leading to bone destruction and marrow failure. MM accounts for approximately 1.8% of all cancers and slightly >15% of hematologic malignancies in the United
Kenneth C. Anderson, Melissa Alsina, William Bensinger, J. Sybil Biermann, Asher Chanan-Khan, Adam D. Cohen, Steven Devine, Benjamin Djulbegovic, Edward A. Faber Jr., Cristina Gasparetto, Carol Ann Huff, Adetola Kassim, Bruno C. Medeiros, Ruby Meredith, Noopur Raje, Jeffrey Schriber, Seema Singhal, George Somlo, Keith Stockerl-Goldstein, Steven P. Treon, Guido Tricot, Donna M. Weber, Joachim Yahalom and Furhan Yunus
NCCN Clinical Practice Guidelines in Oncology for Multiple Myeloma NCCN Categories of Evidence and Consensus Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate. Category 2A
Ruben Niesvizky and Ashraf Z. Badros
Therapies such as thalidomide, bortezomib, and lenalidomide have provided meaningful benefits in multiple myeloma (MM), such as improved response rates and improved duration of response, but they have been associated with an increased risk of
Ashraf Z. Badros
Maintenance therapy in multiple myeloma (MM) comprises any therapy given “following completion of induction treatment in responding or nonprogressing patients, with the goal of prolonging survival.” 1 However, maintenance therapy practice
Jacob P. Laubach, Constantine S. Mitsiades, Anuj Mahindra, Marlise R. Luskin, Jacalyn Rosenblatt, Irene M. Ghobrial, Robert L. Schlossman, David Avigan, Noopur Raje, Nikhil C. Munshi, Kenneth C. Anderson and Paul G. Richardson
Multiple myeloma (MM) is a B-cell neoplasm characterized by aberrant expansion of plasma cells within the bone marrow and extramedullary sites, including cortical bone. It accounts for 10% to 15% of hematologic malignancies, and 20% of deaths
Kenneth C. Anderson, Melissa Alsina, William Bensinger, J. Sybil Biermann, Adam D. Cohen, Steven Devine, Benjamin Djulbegovic, Edward A. Faber Jr, Cristina Gasparetto, Francisco Hernandez-Illizaliturri, Carol Ann Huff, Adetola Kassim, Amrita Y. Krishnan, Michael Liedtke, Ruby Meredith, Noopur Raje, Jeffrey Schriber, Seema Singhal, George Somlo, Keith Stockerl-Goldstein, Steven P. Treon, Donna Weber, Joachim Yahalom, Furhan Yunus, Dorothy A. Shead and Rashmi Kumar
this activity, participants will be able to: Integrate into professional practice the updates to NCCN Guidelines for Multiple Myeloma Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Multiple Myeloma
Timothy M. Schmidt and Natalie S. Callander
framework that is still in use today. 6 His seminal publication tracked the outcome of 241 patients found to have serum monoclonal proteins but no evidence of multiple myeloma (MM) and carefully documented their course with at least 5 years of follow
